お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:慢性閉塞性肺疾患(COPD):パイプライン製品の分析
市場調査レポート
商品コード
264708

慢性閉塞性肺疾患(COPD):パイプライン製品の分析

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 576 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
慢性閉塞性肺疾患(COPD):パイプライン製品の分析
出版日: 2020年10月30日
発行: Global Markets Direct
ページ情報: 英文 576 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性閉塞性肺疾患(COPD)は、肺からの呼気・吸気が不完全となり、息切れを引き起こす肺疾患です。肺への空気の流出入が阻害され、咳、疲労感、胸痛といった症状が時間とともに悪化し、合併症も増加します。第一のリスク要因は喫煙ですが、化学物質や大気汚染などもCOPDの進行要因となります。

当レポートでは、慢性閉塞性肺疾患(COPD)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性閉塞性肺疾患(COPD)の概要

治療薬の開発

治療薬の評価

治療薬の開発に従事している企業

薬剤プロファイル

開発が休止されている製品

開発が中止されている製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apollo Therapeutics LLC, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquilon Pharmaceuticals SA, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ark Biosciences Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Atriva Therapeutics GmbH, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sulfateq BV, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Surrozen Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Symmune Therapeutics LLC, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synovo GmbH, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Tetherex Pharmaceuticals Corp, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TFF Pharmaceuticals Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TGV-Inhalonix Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theratrophix LLC, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unity Biotechnology Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Validus Cellular Therapeutics Inc, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H2 2020
  • Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
目次
Product Code: GMDHC12651IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H2 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 8, 34, 13, 3, 82, 22 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Chronic Obstructive Pulmonary Disease - Overview
  • Chronic Obstructive Pulmonary Disease - Therapeutics Development
  • Chronic Obstructive Pulmonary Disease - Therapeutics Assessment
  • Chronic Obstructive Pulmonary Disease - Companies Involved in Therapeutics Development
  • Chronic Obstructive Pulmonary Disease - Drug Profiles
  • Chronic Obstructive Pulmonary Disease - Dormant Projects
  • Chronic Obstructive Pulmonary Disease - Discontinued Products
  • Chronic Obstructive Pulmonary Disease - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.